PRELOAD PRELOAD PRELOAD PRELOAD PRELOAD

Investors

Press Releases

All Releases
View Summary BioMarin Announces Fourth Quarter and Full Year 2014 Financial Results
Feb 25, 2015
PDF 35.7 KB Add to Briefcase
View Summary BioMarin Pharmaceutical Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Feb 20, 2015
PDF 9.7 KB Add to Briefcase
View Summary Prosensa Announces Voluntary Delisting and Advance Liquidation Distribution
Feb 10, 2015
PDF 8.9 KB Add to Briefcase
View Summary BioMarin Announces 2 Oral and 8 Poster Presentations at Lysosomal Disease Network's 11th Annual WORLD Symposium(TM)
Feb 9, 2015
PDF 103.7 KB Add to Briefcase
View Summary BioMarin to Attend Upcoming Investor Conferences
Feb 4, 2015
PDF 7.9 KB Add to Briefcase
View Summary BioMarin to Host Fourth Quarter and Full Year 2014 Financial Results Conference Call and Webcast on Wednesday, February 25 at 4:30pm ET
Feb 3, 2015
PDF 8.8 KB Add to Briefcase
View Summary BioMarin Announces Final Results of Tender Offer for Prosensa's Shares and Completion of Subsequent Offering Period
Jan 30, 2015
PDF 10.4 KB Add to Briefcase
View Summary BioMarin Announces Underwriters' Full Exercise of Option to Purchase Additional Shares
Jan 23, 2015
PDF 8.6 KB Add to Briefcase
View Summary BioMarin Announces Pricing of Public Offering of Common Stock
Jan 22, 2015
PDF 10.7 KB Add to Briefcase
View Summary BioMarin Announces Public Offering of Common Stock
Jan 21, 2015
PDF 10.9 KB Add to Briefcase
View Summary BioMarin Announces Completion of Tender Offer for Prosensa's Shares and Commences Subsequent Offering Period
Jan 15, 2015
PDF 12.2 KB Add to Briefcase
View Summary BioMarin Provides Preliminary Data From Ongoing Phase 1/2 Pivotal Study of BMN 190 for Treatment of CLN2 Disorder, a Form of Batten Disease
Jan 12, 2015
PDF 11.8 KB Add to Briefcase
View Summary BioMarin Announces Planned Changes to Board of Directors Leadership Structure
Jan 7, 2015
PDF 9.0 KB Add to Briefcase
View Summary BioMarin to Present at the J.P. Morgan Healthcare Conference
Jan 6, 2015
PDF 7.5 KB Add to Briefcase
View Summary BioMarin Announces Approval of VIMIZIM(R) (elosulfase alfa) in Japan for Treatment of Morquio A Syndrome
Dec 29, 2014
PDF 59.3 KB Add to Briefcase
View Summary BioMarin and Prosensa Announce Expiration of the Hart-Scott-Rodino Waiting Period for BioMarin's Proposed Acquisition of Prosensa
Dec 24, 2014
PDF 11.7 KB Add to Briefcase
View Summary BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Brazil for Treatment of Morquio A Syndrome
Dec 10, 2014
PDF 59.2 KB Add to Briefcase
View Summary FDA Grants BioMarin Orphan Drug Designation for NAGLU Fusion Protein, BMN 250, for the Treatment of MPS IIIB (Sanfilippo Syndrome Type B)
Dec 10, 2014
PDF 11.0 KB Add to Briefcase
View Summary BioMarin to Highlight Breadth of Innovative Development Pipeline at Analyst and Investor Day on December 10th in New York
Dec 9, 2014
PDF 10.1 KB Add to Briefcase
View Summary BioMarin's VIMIZIM(R) (elosulfase alfa) Approved in Australia for Treatment of Morquio A Syndrome
Dec 7, 2014
PDF 59.3 KB Add to Briefcase
Showing 1-20 of 331 Page: 1 2 3 4 5 ... 17  Next 20
Add to Briefcase = add release to Briefcase